Tesamorelin Calculator
Tesamorelin (also known as Egrifta) reconstitution and dosage reference — calculate vial concentration, BAC water volume, and exact syringe units below.
At the reference preset of a 5mg Tesamorelin vial reconstituted with 2 mL of bacteriostatic water, a 1mg dose measures 40 units on a U-100 insulin syringe.
Tesamorelin (Egrifta) is an FDA-approved GHRH analogue indicated for the reduction of excess abdominal fat in HIV-associated lipodystrophy.
- Concentration
- 2.5 mg/mL
- Draw volume
- 0.4 mL
- Units (U-100)
- 40
- Doses per vial
- ≈ 5
- Reference preset
- 5mg · 2mL · 1mg
Reference values from the default preset — adjust the calculator below for your vial.
What is Tesamorelin?
Tesamorelin (Egrifta) is an FDA-approved GHRH analogue indicated for the reduction of excess abdominal fat in HIV-associated lipodystrophy. The approved dose is 2 mg subcutaneously once daily. It is also studied off-label for visceral adiposity and cognitive endpoints.
| 1 mg | lyophilized powder |
| 2 mg | lyophilized powder |
| 5 mg | lyophilized powder |
| 10 mg | lyophilized powder |
| 1 mg | ≈ 40 U-100 units (at 5mg / 2mL) |
| 1.4 mg | ≈ 56 U-100 units (at 5mg / 2mL) |
| 2 mg | ≈ 80 U-100 units (at 5mg / 2mL) |
How it's typically prepared
Tesamorelin ships as a lyophilized powder. The Egrifta label specifies reconstitution with sterile water for injection; compounded research vials are reconstituted with bacteriostatic water. Inject the diluent slowly down the inner wall of the vial and swirl gently rather than shaking. Store reconstituted solution refrigerated at 2–8 °C and protect from light. A 5 mg vial reconstituted with 2 mL gives a 2.5 mg/mL concentration, so the labelled 2 mg amount corresponds to 0.8 mL — 80 units on a U-100 insulin syringe.
How tesamorelin is dosed
Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone (GHRH). Rather than supplying growth hormone directly, it prompts the pituitary to release the body's own growth hormone in a physiological pattern, raising IGF-1 downstream. The FDA-approved Egrifta label specifies 2 mg subcutaneously once daily for the reduction of excess abdominal fat in HIV-associated lipodystrophy — the only approved indication. The compound is also cited in research literature for visceral adiposity and cognitive endpoints, but those uses are investigational.
Because tesamorelin is dosed once daily, draw volume on a U-100 insulin syringe depends on the reconstitution. A 5 mg vial in 2 mL of diluent sits at 2.5 mg/mL, so the 2 mg labelled amount is 0.8 mL, or 80 units. A 1 mg vial reconstituted in 1 mL is at 1 mg/mL, so the same 2 mg amount would require two units of volume — which is why vial size and diluent volume both matter. The calculator above converts any vial-and-target combination into syringe units; the figures are a reference, not personalised advice.
Tesamorelin reconstitution reference
Concentration and U-100 insulin-syringe volume for the labelled 2 mg amount at common vial-and-diluent combinations. Use it as a cross-check against the calculator above.
| 2 mg in 1 mL | 2 mg/mL · 2 mg = 1.0 mL · 100 units |
| 5 mg in 2 mL | 2.5 mg/mL · 2 mg = 0.8 mL · 80 units |
| 5 mg in 1 mL | 5 mg/mL · 2 mg = 0.4 mL · 40 units |
| 10 mg in 2 mL | 5 mg/mL · 2 mg = 0.4 mL · 40 units |
Frequently asked questions
- Is tesamorelin FDA-approved?
- Yes — tesamorelin (Egrifta) was approved by the FDA in 2010 for the reduction of excess abdominal fat in HIV-associated lipodystrophy. That is its only approved indication.
- What is the labelled tesamorelin dose?
- The Egrifta label specifies 2 mg subcutaneously once daily. On a 5 mg vial reconstituted in 2 mL (2.5 mg/mL) that is 0.8 mL, or 80 units on a U-100 insulin syringe.
- How does tesamorelin differ from HGH?
- Tesamorelin is a GHRH analogue — it prompts the pituitary to release the body's own growth hormone, rather than supplying growth hormone directly the way recombinant somatropin does. The downstream marker for both is IGF-1.
- What diluent is used to reconstitute tesamorelin?
- The Egrifta label specifies sterile water for injection. Compounded research vials are typically reconstituted with bacteriostatic water. In both cases the solution is stored refrigerated and protected from light.
- How long does a reconstituted tesamorelin vial last?
- Follow the in-use stability window in the specific product's prescribing information. Reconstituted GHRH-analogue solutions are generally stored refrigerated at 2–8 °C and used within the labelled period.
Tesamorelin unit conversions
Pre-built lookup tables that convert Tesamorelin between common units at the reference 5mg / 2mL concentration.
Related references
- Sermorelin — dosage calculator, reconstitution chart, and sources.
- CJC-1295 — dosage calculator, reconstitution chart, and sources.
- Hexarelin — dosage calculator, reconstitution chart, and sources.
PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.